The drug, combined with Celgene's Vidaza, Otsuka's Dacogen or low-dose cytarabine, showed strong response rates in elderly and unfit AML patients, historically a hard-to-treat population.
The data for AMG 420 are early, an Amgen executive said, but where to place the drug relative to CAR-Ts is a "million-dollar question."
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company's adoptive cell therapy produced responses in central nervous system PTLD, a frequently lethal complication of stem cell and solid organ transplants.
The company presented Phase I data from its study of allogeneic CAR-T UCART19, as well as preclinical data on a BCMA CAR-T for multiple myeloma.
A company analysis deemed the patient's myelodysplastic syndrome was unrelated to LentiGlobin, but a news report indicated it may have stemmed from the conditioning regimen used in the trial.
Bispecific antibodies like Amgen's AMG 420 could present some competition to CAR-Ts. But could sequential use of the therapies - which target the same antigen - be possible?
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
After its shares plunged nearly 50 percent in October, Alnylam, the double-stranded RNAi company, is trying to resurrect itself with new data at the annual meeting of the American Society of Hematology (ASH).